2-chloro-6-fluoro-4-iodobenzonitrile | 1297540-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-6-fluoro-4-iodobenzonitrile
• CAS: 1297540-72-7
• 化学式: C₇H₂ClFIN
• 分子量: 281.455
• InChiKey: SPBFQZJKXOTHNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloro-6-fluoro-4-iodobenzonitrile 在 bis-triphenylphosphine-palladium(II) chloride 盐酸 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 3.0h， 生成 2-chloro-6-fluoro-4-(1H-pyrazol-3-yl)benzonitrile
  参考文献：
  名称：

  [EN] ANDROGEN RECEPTOR MODULATING COMPOUNDS
  [FR] COMPOSÉS MODULATEURS DE RÉCEPTEURS DES ANDROGÈNES

  摘要：

  公开号：

  WO2011051540A8
• 作为产物：
  描述：

  4-amino-2-chloro-6-fluorobenzonitrile 在 硫酸 、 sodium nitrite 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 2-chloro-6-fluoro-4-iodobenzonitrile
  参考文献：
  名称：

  ANDROGEN RECEPTOR MODULATING CARBOXAMIDES

  摘要：

  式(I)或(II)的化合物 其中R x ，R z ，R 9 ，R 10 ，R 14 ，R 14 ′，R 15 ，R 15 ′，A和B如权利要求中所定义，并且其药学上可接受的盐和酯已被披露。这些化合物具有作为组织选择性雄激素受体调节剂（SARM）的效用，并且在治疗前列腺癌和其他依赖于AR的疾病和病症中，需要AR拮抗作用时可用作药物。

  公开号：

  US20140094474A1

文献信息

• [EN] ANDROGEN RECEPTOR MODULATING CARBOXAMIDES<br/>[FR] CARBOXAMIDES MODULANT LES RÉCEPTEURS D'ANDROGÈNES
  申请人：ORION CORP

  公开号：WO2012143599A1

  公开（公告）日：2012-10-26

  Compounds of formula (I) wherein Rx, Rz, R9, R10, R14, R14', R15, R15', A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

  公式（I）中的化合物，其中Rx、Rz、R9、R10、R14、R14'、R15、R15'、A和B的定义如索赔中所述，并且其药学上可接受的盐和酯已被披露。这些化合物具有作为组织选择性雄激素受体调节剂（SARM）的效用，并且在治疗前列腺癌和其他依赖于雄激素受体的疾病和病症中特别有用，其中需要AR拮抗作用。
• ANDROGEN RECEPTOR MODULATING COMPOUNDS
  申请人：Wohlfahrt Gerd

  公开号：US20120225867A1

  公开（公告）日：2012-09-06

  The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

  本公开涉及式(I)的化合物及其药学上可接受的盐。本公开还涉及包括式(I)的化合物及其药学上可接受的盐的组合物和治疗方法。
• Androgen receptor modulating compounds
  申请人：Wohlfahrt Gerd

  公开号：US08975254B2

  公开（公告）日：2015-03-10

  The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

  本公开涉及式(I)的化合物及其药学上可接受的盐。本公开还涉及包含式(I)的化合物及其药学上可接受的盐的组合物和治疗方法。
• Androgen receptor modulating carboxamides
  申请人：Törmäkangas Olli

  公开号：US08921378B2

  公开（公告）日：2014-12-30

  Compounds of formula (I) or (II) wherein Rx, Rz, R9, R10, R14, R14′, R15, R15′, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

  公式（I）或（II）的化合物被揭示，其中Rx、Rz、R9、R10、R14、R14'、R15、R15'、A和B在权利要求中定义，并且其药学上可接受的盐和酯。这些化合物具有组织选择性雄激素受体调节剂（SARM）的效用，并且在治疗前列腺癌和其他需要AR拮抗作用的疾病和条件中作为药物是有用的。
• Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants
  作者：Jiang Yu、Peiting Zhou、Mingxing Hu、Liuqing Yang、Guoyi Yan、Ruixue Xu、Yufang Deng、Xinghai Li、Yuanwei Chen

  DOI：10.1016/j.ejmech.2019.111608

  日期：2019.11

  Androgen receptor (AR) has been a target of prostate cancer (PC) for nearly six decades. Recently, downregulating or degrading AR and the mutants especially the splice variant 7 (AR-V7) lacking ligand binding domain (LBD) emerged as an advantageous therapeutic approach to overcome drug resistance. Here, the structural modification of darolutamide resulted in the discovery of dual-action AR inhibitors and down-regulators. Unlike other traditional AR antagonists targeting the AR-LBD, compounds 4k and 4b not only inhibit the activities of wt-AR and AR-F876L mutant but also downregulate the protein expression of full-length (AR-full) and AR variant 7 (AR-V7) at mRNA level. In cell proliferation assays, compounds 4k and 4b exhibited better antiproliferative activities than darolutamide and enzalutamide against AR-V7-positive 22Rv1 cells and VCaP cells. In addition, 4k demonstrated better antitumor activity than clinically used enzalutamide in castration-resistant VCaP xenograft model. Collectively, combining the activities of AR inhibition and downregulation, compound 4k is proposed as an advantageous lead compound to disrupt AR signaling and overcome resistance. (C) 2019 Elsevier Masson SAS. All rights reserved.